Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target.

July 01, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Structure Therapeutics (NASDAQ:GPCR) and maintained a $65 price target.
The reiteration of an Overweight rating and a maintained price target of $65 by a reputable analyst from Cantor Fitzgerald is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100